Northern Trust Corp Macrogenics Inc Transaction History

Northern Trust Corp

  • $586 Billion
  • Q2 2024

A detailed history of Northern Trust Corp transactions in Macrogenics Inc stock. As of the latest transaction made, Northern Trust Corp holds 712,168 shares of MGNX stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
712,168
Previous 732,414 2.76%
Holding current value
$2.16 Million
Previous $10.8 Million 71.93%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$3.31 - $18.51 $67,014 - $374,753
-20,246 Reduced 2.76%
712,168 $3.03 Million
Q1 2024

May 14, 2024
SELL
$9.77 - $21.47 $410,975 - $903,135
-42,065 Reduced 5.43%
732,414 $10.8 Million
Q4 2023

Feb 13, 2024
BUY
$4.48 - $10.11 $19,304 - $43,563
4,309 Added 0.56%
774,479 $7.45 Million
Q3 2023

Nov 13, 2023
BUY
$4.48 - $6.19 $88,618 - $122,444
19,781 Added 2.64%
770,170 $3.59 Million
Q2 2023

Aug 11, 2023
BUY
$4.62 - $7.54 $210,538 - $343,605
45,571 Added 6.47%
750,389 $4.01 Million
Q1 2023

May 15, 2023
SELL
$4.82 - $7.24 $89,618 - $134,613
-18,593 Reduced 2.57%
704,818 $5.05 Million
Q4 2022

Feb 13, 2023
SELL
$3.34 - $6.98 $141,966 - $296,684
-42,505 Reduced 5.55%
723,411 $4.85 Million
Q3 2022

Nov 14, 2022
BUY
$3.01 - $5.22 $582,444 - $1.01 Million
193,503 Added 33.8%
765,916 $2.65 Million
Q2 2022

Aug 12, 2022
SELL
$2.25 - $9.99 $45,218 - $200,769
-20,097 Reduced 3.39%
572,413 $1.69 Million
Q1 2022

May 13, 2022
SELL
$8.12 - $16.9 $243,941 - $507,709
-30,042 Reduced 4.83%
592,510 $5.22 Million
Q4 2021

Feb 08, 2022
SELL
$15.91 - $21.88 $203,632 - $280,042
-12,799 Reduced 2.01%
622,552 $9.99 Million
Q3 2021

Nov 15, 2021
SELL
$19.74 - $28.7 $281,985 - $409,979
-14,285 Reduced 2.2%
635,351 $13.3 Million
Q2 2021

Aug 13, 2021
BUY
$20.49 - $35.63 $803,679 - $1.4 Million
39,223 Added 6.43%
649,636 $17.4 Million
Q1 2021

May 12, 2021
SELL
$18.99 - $33.2 $792,338 - $1.39 Million
-41,724 Reduced 6.4%
610,413 $19.4 Million
Q4 2020

Feb 11, 2021
SELL
$19.41 - $26.0 $13,664 - $18,304
-704 Reduced 0.11%
652,137 $14.9 Million
Q3 2020

Nov 16, 2020
BUY
$24.69 - $31.6 $478,097 - $611,902
19,364 Added 3.06%
652,841 $16.4 Million
Q2 2020

Aug 14, 2020
BUY
$5.2 - $29.12 $64,329 - $360,243
12,371 Added 1.99%
633,477 $17.7 Million
Q1 2020

May 14, 2020
BUY
$4.28 - $12.11 $44,507 - $125,931
10,399 Added 1.7%
621,106 $3.61 Million
Q4 2019

Feb 14, 2020
SELL
$7.95 - $12.27 $263,248 - $406,296
-33,113 Reduced 5.14%
610,707 $6.65 Million
Q3 2019

Nov 13, 2019
BUY
$12.44 - $17.48 $1.09 Million - $1.53 Million
87,317 Added 15.69%
643,820 $8.22 Million
Q2 2019

Aug 13, 2019
BUY
$14.51 - $19.71 $88,351 - $120,014
6,089 Added 1.11%
556,503 $9.44 Million
Q1 2019

May 13, 2019
BUY
$11.11 - $25.6 $287,904 - $663,398
25,914 Added 4.94%
550,414 $9.9 Million
Q4 2018

Feb 12, 2019
BUY
$11.75 - $21.42 $19,317 - $35,214
1,644 Added 0.31%
524,500 $6.66 Million
Q3 2018

Nov 14, 2018
BUY
$19.26 - $23.46 $175,266 - $213,486
9,100 Added 1.77%
522,856 $11.2 Million
Q2 2018

Sep 18, 2018
SELL
$19.78 - $24.67 $47,096 - $58,739
-2,381 Reduced 0.46%
513,756 $10.6 Million
Q2 2018

Aug 14, 2018
BUY
$19.78 - $24.67 $1.63 Million - $2.04 Million
82,614 Added 19.06%
516,137 $10.7 Million
Q1 2018

May 09, 2018
BUY
$18.89 - $32.46 $24,557 - $42,198
1,300 Added 0.3%
433,523 $10.9 Million
Q4 2017

Feb 14, 2018
BUY
$16.19 - $20.3 $30,113 - $37,758
1,860 Added 0.43%
432,223 $8.21 Million
Q3 2017

Nov 13, 2017
BUY
$15.52 - $18.94 $6.68 Million - $8.15 Million
430,363
430,363 $7.95 Million

Others Institutions Holding MGNX

# of Institutions
154
Shares Held
60.6M
Call Options Held
218K
Put Options Held
259K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $187M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email